SynthesisBMC nephrology2026
Prognostic value of vascular lesions in immunoglobulin a nephropathy: a meta-analysis.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeImmunoglobulin A nephropathy (IgAN) stands as the most frequently observed primary glomerular disease globally and a major contributor to end-stage renal disease (ESRD). The aim of this study is to investigate the prognostic value of vascular lesions in IgAN through meta-analysis.
methodsFour databases, comprising Embase, Cochrane Library, PubMed, and Web of Science, were comprehensively searched from the commencement of each database to November 8, 2025. The quality of all eligible studies was evaluated utilizing the Newcastle-Ottawa scale (NOS). Statistical analysis was implemented using Stata (version 18.0). The association between vascular lesions in IgAN and adverse kidney outcomes was assessed by pooling hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs).
resultsTotally 16 studies from 6 countries, involving 8,862 patients, were included. Among patients with IgAN, arteriosclerotic lesions increased the risk of poor kidney outcomes (HR = 1.95; 95%CI: 1.47, 2.60; P < 0.001). Similarly, microangiopathy (MA) triggered an elevated risk of adverse kidney outcomes (HR = 1.98; 95%CI: 1.54, 2.56; P < 0.001). Vascular lesions significantly raised this risk (HR = 2.27; 95%CI: 1.78, 2.91; P < 0.001). After adjustment for confounders, HRs remained statistically significant, indicating that both MA and arterial lesions were associated with adverse outcomes in IgAN.
conclusionIndividuals suffering from IgAN with vascular lesions, including arteriosclerotic lesions and/or microangiopathy, are confronted with a pronouncedly elevated risk of experiencing poor kidney outcomes. After adjusting for available confounding factors, vascular lesions are associated with adverse renal prognosis in patients with IgAN. CLINIC TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.